Insider Trading Activity For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
David P Schenkein , CEO of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reportedly Sold 27,000 shares of the company’s stock at an average price of 59.95 for a total transaction amount of $1,618,650.00 SEC Form
Insider Trading History For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Analyst Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
These are 3 Hold Ratings, 8 Buy Ratings .
The current consensus rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Buy (Score: 2.73) with a consensus target price of $67.25 , a potential (6.68% upside)
Analyst Ratings History For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
- On 11/9/2015 Roth Capital Lower Price Target of rating Neutral with a price target of $114.00 to $75.00
- On 5/18/2016 SunTrust Banks, Inc. Boost Price Target of rating Buy with a price target of $57.00 to $65.00
- On 6/13/2016 J P Morgan Chase & Co Upgraded rating Neutral to Overweight with a price target of $50.00 to $62.00
- On 8/10/2016 Goldman Sachs Group, Inc. (The) Reiterated Rating Neutral with a price target of $46.00
- On 8/19/2016 BTIG Research Initiated Coverage of rating Neutral
- On 12/16/2016 Needham & Company LLC Reiterated Rating Buy with a price target of $60.00 to $54.00
- On 1/17/2017 CIBC Upgraded rating Market Perform to Outperform
Recent Trading Activity for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals, Inc. closed the previous trading session at 63.04 up +1.40 2.27% with 932,987 shares trading hands.